Medical Policy: 07.01.71
Original Effective Date: January 2016
Reviewed: January 2019
Revised: January 2018
This policy contains information which is clinical in nature. The policy is not medical advice. The information in this policy is used by Wellmark to make determinations whether medical treatment is covered under the terms of a Wellmark member's health benefit plan. Physicians and other health care providers are responsible for medical advice and treatment. If you have specific health care needs, you should consult an appropriate health care professional. If you would like to request an accessible version of this document, please contact customer service at 800-524-9242.
Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program.
This Medical Policy document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged or new medical literature may have been published. This Medical Policy will be reviewed regularly and be updated as scientific and medical literature becomes available.
Responsive neurostimulation (RNS) consists of a cranially implanted, programmable cortical neurostimulator for the treatment of partial (focal) epilepsy that involves the use of 1 or more implantable electrode leads that serve as both a seizure detection and neurostimulation function. The device provides what the manufacturer refers to as “responsive cortical stimulation.” The device is programmed using a proprietary algorithm to recognize seizure patterns from electrocorticography output (an electroencephalogram made with electrodes that are in direct contact with the brain) and to deliver electrical stimulation with the goal of terminating a seizure before onset.
Neurostimulation devices are classified as one of two types: chronic programmed stimulation devices that administer stimulation at regular preprogrammed intervals (continuous or intermittent) and responsive neurostimulation (RNS) devices that deliver stimulation directly to the brain at the seizure focus only in response to device-detected, abnormal electrical brain activity. The chronic programmed stimulation methods available for treating epilepsy include vagus nerve stimulation (VNS). Responsive neurostimulation is intended to reduce seizures in patients diagnosed with partial (focal) onset of seizures that are refractory to medical therapy and are not candidates for surgical resection.
There are two broad categories of seizures: focal (or partial) and generalized. Focal (partial) seizures involve only a portion of the brain, typically part of one lobe of one hemisphere. A focal (partial) seizure can be associated with impairment of consciousness or awareness (previously called complex partial seizure) or no impairment of consciousness (previously called simple partial seizures). A focal (partial) seizure can evolve over seconds into a tonic-clonic convulsion, also referred to as a secondary generalized seizure.
The primary treatment option for epilepsy is drug therapy consisting of one more antiepileptic drugs. However, many cases of epilepsy do not respond adequately to drug therapy. Medically refractory epilepsy is defined as “failure of adequate trials of two tolerated and appropriately chosen and used antiepileptic drug schedules to achieve sustained seizure freedom.” A second or third line option for these patients is surgical resection or transection of the seizure focus, which is considered to be the most effective therapy; however, some patients are not candidates for this type of surgery. Patients may not be candidates for surgery because seizure foci may be unidentifiable or because of overlap with vital areas of the brain. Treatment options are very limited for patients with medically refractory epilepsy who are not candidates for surgical resection. These patients may pursue alternative treatments which includes neurostimulation.
Responsive neurostimulation (RNS) shares some features with deep brain stimulation (DBS), but is differentiated by its use of direct cortical stimulation and by its use in both monitoring and stimulation. The RNS system provides stimulation in response to detection of specific epileptiform patterns, while DBS provides continuous or intermittent stimulation at preprogrammed settings.
The development of RNS system arose from observations related to the effects of cortical electrical stimulation for seizure location. It has been observed that electrical cortical stimulation can terminate induced and spontaneous electrographic seizure activity. Patients with epilepsy may undergo implantation of subdural monitoring electrodes for the purposes of seizure localization, which at times have been used for neurostimulation to identify eloquent brain regions. Epileptiform discharges that occur during stimulation for localization can be stopped by a train of neighboring brief electrical stimulations.
In tandem with the recognition that cortical stimulation can stop epileptiform discharges was development of fast pre-ictal seizure prediction algorithms. These algorithms interpret electrocorticographic data from detection leads situated over the cortex. The RNS process thus includes electrocortiocgraphic monitoring via cortical electrodes, analysis of data through a proprietary seizure detection algorithm, and delivery of electrical stimulation via both cortical and deep implanted electrodes in an attempt to halt a detected epileptiform discharge.
One device, the Neuropace RNS System, is currently approved by the FDA and is commercially available in the United States. The system consists of the implant and external components. The implant is the RNS neurostimulator (generator) and leads (tiny wires containing electrodes connected to the target areas of the brain). The neurostimulator is a battery powered microprocessor-controlled generator that is placed within the skull and beneath the scalp. It connects to one or two leads inserted into the brain (depth lead) and on the brain surface in the area of the seizure focus (cortical strip lead). Both the depth lead(s) and the cortical strip lead(s) can detect the electrical activity of the brain and deliver stimulation. The external components include the programmer, remote monitor, telemetry wand and a patient data management system. The programmer providers the clinicians with a user interface to select and download operating parameters to the RNS neurostimulator for detection and responsive stimulation settings, to view real time ECoG signals, to test the RNS system integrity, and to upload data and diagnostic information from the neurostimulator for review. The remote monitor is a home use monitoring device used to collect data from the RNS neurostimulator and upload the data using telephone lines to the internet by way of a secure connection to the PDMS (patient data management system). The uploaded data are accessible for review by clinicians by way of a secure connection to the PDMS. This offers a convenient option for remotely monitoring the RNS neurostimultor between patient visits to the clinic. The patient data management system (PDMS) is a secure website that provides a means for a clinician to review information that has been transmitted by the programmer and remote monitor.
Before device implantation, the patient undergoes seizure localization, which includes video-EEG monitoring and magnetic resonance imaging for detection of epileptogenic lesions. Additional testing may also include EEG with intracranial electrodes, intraoperative or extraoperative stimulation with subdural electrodes, additional imaging studies, and/or neuropsychological testing and intracarotid amytal (Wada) testing. The selection and location of the leads are based on the location of seizure foci. Cortical strip leads are recommended for seizure on the cortical surface, while the depth leads are recommended for seizure foci beneath the cortical surface. The neurosurgeon performs a scalp incision and then drills two to four burr holes in the skull to allow for lead placement. The surgeon typically implants the depth leads using specialized localization tools and planning software and implants the cortical strip leads on the brain surface under the dura. After securing the leads the surgeon removes the area of skull that conforms precisely to the neurostimulator (craniotomy) to accommodate the neurostimulator. The neurostimulator rests in a frame above the dura and does not touch the brain. After connecting the leads to the neurostimulator, the surgeon programs the neurostimulator for initial use to detect electrocorticographic activity. Responsive therapy is initially set up using standard parameters from the electrodes from which electrical activity is detected. Over time, the responsive stimulation settings are adjusted on the basis of electrocorticography data, which are collected by the patient through interrogation of the device with the telemetry wand and transmitted to the data management system.
The RNS system was approved on the basis of date from there trials: an initial Feasibility study, the Pivotal Trial and a Long Term Treatment Investigation trial (LTT).
The Feasibility study was a multi-center clinical investigation of individuals with medically intractable epilepsy. Sixty-five subjects were implanted with the RNS neurostimulator and leads in the feasibility study. Eligible subjects were 18-65 years of age with medically intractable partial onset seizures and a minimum of 4 simple partial seizures (motor or sensory), complex partial seizures, and/or secondarily generalized seizures in each of the previous three months. Subjects were required to be on a stable antiepileptic medication regimen and must have previously undergone diagnostic testing and localized one or two epileptogenic region(s). Subjects with psychogenic or non-epileptic seizures, status epilepticus, active psychosis, severe depression, or suicidal ideation within the preceding year were excluded. The first four subjects implanted with the RNS neurostimulator and leads at a clinical site participated in an open label protocol (all subjects received responsive neurostimulation), and subsequent subjects at that site participated in a randomized, double-blind, concurrent sham-stimulation control protocol in which the treatment group received stimulation and sham group did not. Forty-two subjects were in the open label protocol and 23 were in the blinded protocol. Following completion of the 16 week evaluation period, subjects transitioned to an open label period, and all subjects were able to receive responsive stimulation. Subjects continued in the open label period through the end of the study participation, which was 2 years post implantation. The Feasibility study was designed to evaluate preliminary safety and effectiveness. The results were used to inform the design of the Pivotal Study and to assess the integrity of the blind.
The Pivotal Trial results were reported by Morrell (2011). This study involved the use of the RNS system in a randomized, double-blinded, multi-center, sham-controlled clinical investigation that initially enrolled 240 subjects. A total of 49 subjects were excluded prior to implantation, leaving 191 subjects for analysis. Eligible subjects were 18-70 years of age, partial onset seizures refractory to at least two trials of anti-epileptic drugs, had experienced at least three disabling seizures per month and had either one or two epileptogenic region(s) localized. All subjects underwent implantation of the RNS system followed by one month break-in period followed by randomization. Subjects were assigned to either active or sham therapy, and followed for the 12 week blinded treatment phase, then an 84 week open-label period where all subjects received active therapy. The authors reported that the blind was successfully maintained (blinding index 0.5727). Both groups experienced a reduction in mean seizure frequency during the first post-implant month prior to randomization. However, this reduction abated during the blinded period in the sham group until, in the final month of the blinded period, seizure frequency approached pre-implant levels. Mean seizure frequency was significantly reduced in the treatment group vs. the sham group (p=0.012) during the blinded period. The responder rate (percentage of subjects with a > 50% reduction in seizures) over the blinded period was not significant overall, with 29% in the treatment group responding versus 27% in the sham group. However, seizure free day over the first month continued to increase in the treatment group but declined for the sham group. By the third month, the treatment group had 27% fewer days with seizures versus 16% fewer days in the sham group (p=0.048). During the open-label period, the sham group demonstrated a statistically significant reduction in mean seizure frequency compared to the pre-implant period (p=0.04). Across all subjects, the reduction was sustained, and even improved, over time. The responder rate at one year post-implant was 43% (n=177) and 46% (n=102) at 2 years. As of the data cutoff date, 13 subjects (7.1%) were seizure free over the most recent 3 month period. The Quality of Life in Epilepsy-89 (QOLIE-89) assessment tool overall t-scores were significantly improved in both groups at the end of the blinded period (p=0.040), 1 year (p,0.001) and 2 years (p=0.016). During the blinded period, there was no difference between the treatment and sham groups in the frequency of cognitive adverse events, or any neuropsychological measure through 2 years. No adverse changes in mood inventories were reported at any time point in the study. The serious adverse event rate for medical and surgical events for the first 84 weeks was 18.3%. This compares favorably to comparator rates for deep brain stimulation (DBS). There was no difference between the treatment and sham groups in the percentage of subjects with mild or serious adverse events over the blinded period, and included intracranial hemorrhage due to surgical complications and subdural hematomas attributed to seizure-related head trauma. Six subjects died, but not were attributed to responsive cortical stimulation treatment. The authors concluded, improvements in QOL (quality of life) overall and in domains related to health concerns, social functioning, and cognition support the clinical meaningfulness of the treatment response. Safety was acceptable compared to alternative and comparable procedures and to the risks of frequent seizures. Stimulation was well tolerated and there were no adverse effects on cognition or mood. Given these findings, responsive cortical stimulation may provide another much-needed treatment option for persons with medically intractable partial seizures.
The final part of the FDA submission data came from the Long-Term Treatment Study (LTT) is an ongoing open-label multi-center prospective clinical study of those subjects who completed the Feasibility trial (57 subjects) and the Pivotal Trial (173 subjects), for a total of 230 subjects. During the LTT study, subjects can continue to receive responsive stimulation. Each subject participates for a maximum of 7 years. Adverse event and seizure data are collected at 6 month intervals, and data regarding quality of life are collected at yearly intervals. Antiepileptic drug adjustments are permitted as needed.
The first published report data from the Long-Term Treatment Study (LTT) was made available in 2015 (Bergey 2015). This report included data from 191 subjects who have completed data at the 6 year cutoff point, but data are presented based on the entire subject pool. The median reduction seizures was 60% at 3 years and 66% at 6 years. The responder rates at the same time points were 58% and 59%. Adjusted response rates taking into account withdrawls at the same time points were 58% and 56%. Based on data from the last 3 months of the collection period, 84% of subjects had some improvement, 60% had 50% or greater reduction in seizure frequency, and 16% were seizure free. Only 8% had a 50% or greater increase in seizure activity. Over one-third of subjects experienced a 3 month seizure free interval, and 23% experienced one of 6 months or longer. QOLIE-89 measures through year 5 continued to improve significantly (p<0.001). Serious events were reported in 2.5% or more of the subject at any time during the study period. Three intracranial hemorrhages were reported at 18 months, 2.5 years and 2.8 years following device implantation. Death was reported for 11 subjects, including 2 suicides, 1 status epilepticus, 1 lymphoma and 7 possible SUDEP (sudden unexpected death in epilepsy). The device was off at the time of 2 SUDEP deaths. The authors concluded these results are promising, and demonstrate continued significant benefit to the use of the RNS system in subjects with epilepsy.
For individuals who have refractory focal (partial) epilepsy who receive responsive neurostimulation (RNS), the evidence includes an industry sponsored randomized controlled trial (RCT), which was used for Food and Drug Administration (FDA) approval of the NeuroPace RNS system. The Pivotal Trial was well-designed and well conducted; it reported that RNS is associated with improvements in mean seizure frequency of about 20% between groups, though the percentage of treatment responders with at least a 50% reduction in seizures did not differ from sham control. Overall, the results suggested a modest reduction in seizure frequency in a subset of patients. The number of adverse events reported in available studies is low. Generally, patients who are candidates for responsive neurostimulation (RNS) are severely debilitated and have few other treatment options, so the benefits are likely high relative to risk. In particular, patients who are not candidates for respective epilepsy surgery and have few treatment options may benefit from RNS. The evidence is sufficient to determine that technology results in a meaningful improvement in the net health outcome.
There were no practice guideline or position statements identified.
November 2013, the NeuroPace RNS system (Neuropace Inc., Mountain View, CA) was approved by the FDA through the premarket approval process for the following indication:
“The RNS System is an adjunctive therapy in reducing the frequency of seizures in individuals 18 years of age or older with partial onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or more antiepileptic medications, and currently have frequent and disabling seizures (motor partial seizures, complex partial seizures and/or secondary generalized seizures). The RNS System has demonstrated safety and effectiveness in patients who average 3 or more disabling seizures per month over the three most recent months (with no month with fewer than two seizures), and has not been evaluated in patients will less frequent seizures.”
Not applicable
See also medical policy 07.01.60 Vagus Nerve Stimulation (VNS) and Vagal Blocking Therapy
Responsive neurostimulation (RNS) may be considered medically necessary for patients with partial (focal) epilepsy who meet ALL of the following criteria:
A replacement or revision of a responsive neurostimulation (RNS) (generator, leads and/or battery) may be considered medically necessary for an individual who meet ALL of the above criteria and the existing device is no longer under warranty and cannot be repaired.
Responsive neurostimulation (RNS) is considered investigational for all other indications not listed above as there is insufficient evidence to support the safety and effectiveness.
To report provider services, use appropriate CPT* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes and / or diagnosis codes.
Wellmark medical policies address the complex issue of technology assessment of new and emerging treatments, devices, drugs, etc. They are developed to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. Wellmark medical policies contain only a partial, general description of plan or program benefits and do not constitute a contract. Wellmark does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Wellmark or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. Our medical policies may be updated and therefore are subject to change without notice.
*CPT® is a registered trademark of the American Medical Association.